Guidance for the 2026/27 financial year
ANNOUNCEMENT NO. 312
10 September 2026
ChemoMetec today approved the annual report for 2025/26, including the guidance for 2026/27, which is considered inside information.
For the financial year 2026/27, ChemoMetec expects revenue in the range of DKK 545-575 million (2025/26: DKK 511.1 million) and EBITDA in the range of DKK 300-315 (2025/26: DKK 281.3 million).
The annual report for 2025/26, which is released along with this announcement, sets out the underlying assumptions applied in the preparation of the guidance for 2026/27 (p. 40-41).
Additional information
Martin Helbo Behrens, CEO
Tel.: (+45) 81 10 06 80
Phillip Massie Price, CFO
Tel.: (+45) 81 10 06 80
About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.
ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go towww.chemometec.com.
© 2026 GlobeNewswire, Inc. All Rights Reserved.
